Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Hedgehog pathway inhibition and the race against tumor evolution.

Atwood SX, Chang AL, Oro AE.

J Cell Biol. 2012 Oct 15;199(2):193-7. doi: 10.1083/jcb.201207140.

2.

Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.

Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE.

Future Oncol. 2015 Nov;11(22):2997-3002. doi: 10.2217/fon.15.181. Epub 2015 Oct 5. Review.

PMID:
26437034
3.

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH Jr, Beachy PA, Rudin CM.

Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3.

4.

Clinical experience with Hedgehog pathway inhibitors.

Low JA, de Sauvage FJ.

J Clin Oncol. 2010 Dec 20;28(36):5321-6. doi: 10.1200/JCO.2010.27.9943. Epub 2010 Nov 1.

PMID:
21041712
5.

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.

Metcalfe C, de Sauvage FJ.

Cancer Res. 2011 Aug 1;71(15):5057-61. doi: 10.1158/0008-5472.CAN-11-0923. Epub 2011 Jul 19. Review. Erratum in: Cancer Res. 2011 Sep 15;71(18):6087.

6.

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.

7.

Hedgehog Pathway Inhibition.

Sekulic A, Von Hoff D.

Cell. 2016 Feb 25;164(5):831. doi: 10.1016/j.cell.2016.02.021.

8.

Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.

Mohan SV, Chang AL.

Semin Cutan Med Surg. 2014 Jun;33(2):68-71. Review.

PMID:
25085664
9.

Advanced treatment for basal cell carcinomas.

Atwood SX, Whitson RJ, Oro AE.

Cold Spring Harb Perspect Med. 2014 Jul 1;4(7):a013581. doi: 10.1101/cshperspect.a013581. Review.

10.

Harnessing hedgehog for the treatment of basal cell carcinoma.

Harms KL, Dlugosz AA.

JAMA Dermatol. 2013 May;149(5):607-8. doi: 10.1001/jamadermatol.2013.448. No abstract available.

PMID:
23677088
11.

Smoothened inhibitors in the treatment of advanced basal cell carcinomas.

Kunstfeld R.

Curr Opin Oncol. 2014 Mar;26(2):184-95. doi: 10.1097/CCO.0000000000000058. Review.

PMID:
24469022
12.
13.

Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.

Kean S.

Science. 2009 Sep 4;325(5945):1188. doi: 10.1126/science.325_1188. No abstract available.

PMID:
19729622
14.

Hedgehog signaling in basal cell carcinoma.

Otsuka A, Levesque MP, Dummer R, Kabashima K.

J Dermatol Sci. 2015 May;78(2):95-100. doi: 10.1016/j.jdermsci.2015.02.007. Epub 2015 Feb 23. Review.

PMID:
25766766
15.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

16.

Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.

Ruiz Salas V, Alegre M, Garcés JR, Puig L.

Expert Rev Anticancer Ther. 2014 Jun;14(6):741-9. doi: 10.1586/14737140.2014.895326. Epub 2014 Mar 10. Review.

PMID:
24611655
17.

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1173-8. doi: 10.1056/NEJMoa0902903. Epub 2009 Sep 2.

18.

PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.

Metcalfe C, Alicke B, Crow A, Lamoureux M, Dijkgraaf GJ, Peale F, Gould SE, de Sauvage FJ.

Cancer Res. 2013 Dec 1;73(23):7034-42. doi: 10.1158/0008-5472.CAN-13-1222. Epub 2013 Oct 23.

19.

Clinical implications of hedgehog signaling pathway inhibitors.

Liu H, Gu D, Xie J.

Chin J Cancer. 2011 Jan;30(1):13-26. Review.

20.

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.

Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ.

Cancer Res. 2011 Jan 15;71(2):435-44. doi: 10.1158/0008-5472.CAN-10-2876. Epub 2010 Dec 1.

Supplemental Content

Support Center